Updates to recommendations for vaccination against respiratory syncytial virus (RSV) in older adults to reflect NIAC’s October 2025 updated recommendations.
Epidemiology updated to reflect 2024/2025 season and increased detail on epidemiology in older adults.
Vaccine efficacy, effectiveness, co-administration and adverse effects data updated to include results of recently published studies.
Information about mRNA-1345 (mResvia, Moderna) included.
Minor formatting changes to align with house style.
V1 28 August 2025
Removed detailed guidance on the use of pavilizumab, as pavilizumab, while authorised in the European Union, is no longer available for use in Ireland. Minor updates to recommendations for immunisation of infants and high-risk children to reflect NIAC’s March 2025 updated recommendations for the passive immunisation of infants against respiratory syncytial virus (RSV).
Minor formatting changes throughout to align with house style.
